Obesity is an epidemic and a public health threat. Medical weight management remains one
of the options for the treatment of excess weight and recent advances have revolutionized …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

The prevalence of obesity has reached pandemic proportions, and now approximately 25%
of adults in Westernized countries have obesity. Recognized as a major health concern …

Obesity is now recognised as a disease that is associated with serious morbidity and
increased mortality. One of its main metabolic complications is type 2 diabetes, as the two …

Background Pharmacotherapy provides an option for adults with overweight and obesity to
reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

The prevalence of heart failure is on the rise and imposes a major health threat, in part, due
to the rapidly increased prevalence of overweight and obesity. To this point …

Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …